Cargando…
Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma
Glioma is a malignant tumor with the highest incidence among all brain tumors (about 46% of intracranial tumors) and is the most common primary intracranial tumor. Among them, glioblastoma (GBM) is highly malignant and is one of the three refractory tumors with the highest mortality rate in the worl...
Autores principales: | Wu, Hao, Liu, Jialin, Wang, Zhifei, Yuan, Wen, Chen, Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446212/ https://www.ncbi.nlm.nih.gov/pubmed/34363319 http://dx.doi.org/10.1111/cns.13714 |
Ejemplares similares
-
Targeting CD47 for cancer immunotherapy
por: Jiang, Zhongxing, et al.
Publicado: (2021) -
CD47-Blocking Antibodies and Atherosclerosis
por: Ryan, John J.
Publicado: (2016) -
Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma
por: Gholamin, Sharareh, et al.
Publicado: (2019) -
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020) -
CD47–SIRPα-targeted therapeutics: status and prospects
por: Maute, R., et al.
Publicado: (2022)